Clinical Trial

SWIFT: Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy

Study acronym: SWIFT
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The overall goal of the Study of Women, Infant Feeding and Type 2 Diabetes after GDM pregnancy (SWIFT) is to determine the relation of longer and more intensive lactation, as compared to formula feeding, on progression to incident type 2 diabetes mellitus among women within several years following delivery of a GDM pregnancy. The initial study enrolled women with recent GDM at 6 to 9 weeks post-delivery to reclassify oral glucose tolerance and conduct subsequent testing of glucose tolerance to ascertain progression to overt diabetes up to two years later. Research methods were utilized to assess lactation intensity and duration quantitatively and to evaluate incidence rates of diabetes, as well as changes in blood glucose levels, insulin resistance, body weight, waist circumference, and overall adiposity from baseline and up to several years later. SWIFT is a prospective, observational cohort study of 1,035 women recruited during pregnancy who were diagnosed with gestational diabetes mellitus (GDM) via Carpenter and Coustan criteria and enrolled into the research study. We assessed the natural history of progression to prediabetes and type 2 diabetes from early postpartum for a racially and ethnically diverse cohort of women with GDM (75% minority) at high-risk for developing overt diabetes within 5-10 years post-delivery.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2013-10-17; most recent amendment 2024-10-07.
Trial Details
NCT Number NCT01967030
Lead Sponsor Kaiser Permanente
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Diabetes Association, W.K. Kellogg Foundation, Centers for Disease Control and Prevention, National Heart, Lung, and Blood Institute (NHLBI), University of Toronto
Conditions Type 2 Diabetes
Enrollment 1,035 participants
Start Date 2008-05
Primary Completion 2030-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2024-10-08